| abstract |
The invention relates to an RNA vaccine comprising at least one RNA comprising an open reading frame (ORF) encoding at least one antigen and at least one PD-1 pathway inhibitor, preferably a PD-I receptor or a ligand PD- RTI ID = 0.0 > PD-1 < / RTI > pathway inhibitor for PD-L1 and PD-L2. The present invention also relates to pharmaceutical compositions and kit of parts comprising the components of such vaccine / inhibitor combinations. The present invention also relates to such vaccine / inhibitor combinations, pharmaceutical compositions and kit (s), including vaccine / inhibitor combinations, in particular vaccine / inhibitor combinations, for the prevention or treatment of tumor or cancer diseases or infectious diseases, of parts for use in medical applications. The present invention also relates to the use of an RNA vaccine for use in therapy in combination with a PD-1 pathway inhibitor and the use of a PD-1 pathway inhibitor for use in combination with an RNA vaccine. |